Peng Cao

Dr. Peng Cao

Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2023 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
PCPeng Cao
Peng Cao
YWYi Wang
Yi Wang
CZCong Zhang
Cong Zhang
MSMitchell A. Sullivan
Mitchell A. Sullivan
WCWen Chen
Wen Chen
Lianxiang LuoLianxiang Luo
Lianxiang Luo

1 May 2018 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
PCPeng Cao
Peng Cao
JSJinlu Sun
Jinlu Sun
MSMitchell A. Sullivan
Mitchell A. Sullivan
XHXiao Huang
Xiao Huang
HWHanxiang Wang
Hanxiang Wang
KWKaiping Wang
Kaiping Wang

1 July 2020 in Carbohydrate Polymers
Verified
Journal Article
Closed access
PCPeng Cao
Peng Cao
SWSanlan Wu
Sanlan Wu
TWTingting Wu
Tingting Wu
YDYahui Deng
Yahui Deng
QZQilin Zhang
Qilin Zhang
YZYu Zhang
Yu Zhang

19 January 2015 in Food & Function
Verified
Journal Article
Closed access
PDF file
KWKaiping Wang
Kaiping Wang
PCPeng Cao
Peng Cao
WSWeizhi Shui
Weizhi Shui
QYQiuxiang Yang
Qiuxiang Yang
ZTZhuohong Tang
Zhuohong Tang
YZYu Zhang
Yu Zhang
The present study was designed to evaluate the potential hypoglycemic and hypolipidemic effects of Angelica sinensis polysaccharide (ASP), purified from the fresh roots of Angelica sinensis (AS), in prediabetic and streptozotocin (STZ)-induced diabetic BALB/c mice. It was observed that fasting blood glucose (FBG) levels in both models were reduced after a 4-week oral administration of ASP or metformin, and abnormal fasting serum insulin (FINS) concentrations were ameliorated as well. Moreover, the homeostasis model assessment-insulin resistance (HOMA-IR) index was decreased strikingly and body weight (BW) was reduced significantly in prediabetic mice after treatment with ASP. In addition, ASP also contributed to improving the dyslipidemia conditions. Elevated serum total cholesterol (TC) or triglyceride (TG) concentrations were reduced after treatment with ASP in prediabetic mice or STZ-induced diabetic mice. Meanwhile, hepatic glycogen (HG) and muscle glycogen (MG) concentrations were increased while insulin resistance (IR)-related inflammatory factors IL-6 and TNF-α in serum were reduced in STZ-induced diabetic mice. Histopathological examination indicated that the impaired pancreatic/hepatic tissues or adipose tissues were effectively restored in STZ-induced diabetic mice or prediabetic mice after the ASP treatment. Taken together, these results revealed that ASP efficiently exerted hypoglycemic and hypolipidemic benefits, and its potential effect was associated with the amelioration of IR. ASP can be applied in the prevention and treatment of diabetes.

18 May 2016 in Scientific Reports
Verified
Journal Article
Open access
KWKaiping Wang
Kaiping Wang
PCPeng Cao
Peng Cao
HWHanxiang Wang
Hanxiang Wang
ZTZhuohong Tang
Zhuohong Tang
NWNa Wang
Na Wang
YZYu Zhang
Yu Zhang
This study aimed to investigate the therapeutic effects of Angelica sinensis polysaccharide (ASP), an active component derived from a water extract of Angelica sinensis, in high-fat diet (HFD)-fed BALB/c mice. The potential mechanisms underlying the activity of this compound were also considered. Specifically, serum and hepatic biochemical parameters were evaluated and key proteins involved in the lipid/glucose metabolism were analyzed. Long-term feeding with a HFD induced severe fatty liver and hyperglycemia. Histological examination clearly showed that ASP reduced lipid accumulation in the liver and attenuated hepatic steatosis in HFD-fed mice. In addition, ASP markedly alleviated serum and liver lipid disorders and fatty liver via the upregulation of PPARγ expression and the activation of adiponectin-SIRT1-AMPK signaling. Furthermore, ASP also significantly relieved severe oxidative stress, demonstrating that ASP might attenuate nonalcoholic fatty liver disease via a “two-hit” mechanism. In addition, ASP reduced blood glucose levels and ameliorated insulin resistance via the regulation of related metabolic enzymes and by activating the PI3K/Akt pathway in HFD-fed mice. Our findings revealed that ASP might be used as an alternative dietary supplement or health care product to ameliorate metabolic syndrome in populations that consistently consume HFDs.

14 September 2022 in Food & Function
Verified
Journal Article
Closed access
PDF file
PCPeng Cao
Peng Cao
YWYue Wu
Yue Wu
YLYaping Li
Yaping Li
LXLiping Xiang
Liping Xiang
BCBingyu Cheng
Bingyu Cheng
JHJiangeng Huang
Jiangeng Huang
Alcoholic liver disease (ALD) is a mounting public health problem with significant medical, economic and social burdens. Tartary buckwheat (F. tataricum (L.) Gaertn, bitter buckwheat) is a kind of healthy and nutritious food, which has been demonstrated to protect against ALD, but the underlying mechanism has not been fully studied. Herein, we aimed to elucidate the beneficial effects of Tartary buckwheat extract (mainly composed of polyphenols including rutin, quercetin, kaempferol and kaempferol-3-O-rutinoside) in terms of lipid metabolism with the aid of lipidomic analysis. In our study, we employed C57BL/6J mice and a Lieber–DeCarli alcohol liquid diet to construct an ALD model and found that Tartary buckwheat extract was able to prevent ALD-induced histopathological lesions, liver injury and abnormal plasma lipid levels. These beneficial effects might be attributed to the regulation of energy metabolism-related genes (SIRT1, LKB1 and AMPK), lipid synthesis-related genes (ACC, SREBP1c and HMGR) and lipid oxidation-related genes (PPARα, CPT1 and CPT2). In addition, lipidomic profiling and KEGG pathway analysis showed that glycerophospholipid metabolism contributed the most to elucidating the regulatory mechanism of Tartary buckwheat extract. In specific, chronic ethanol intake reduced the level of phosphatidylcholines (PC) and increased the level of phosphatidylethanolamines (PE) in the liver, resulting in a decrease in the PC/PE ratio, which could be all significantly restored by Tartary buckwheat extract intervention, indicating that the Tartary buckwheat extract might regulate PC/PE homeostasis to exert its lipid-lowering effect. Overall, we demonstrated that Tartary buckwheat extract could prevent ALD by modulating hepatic glycerophospholipid metabolism, providing the theoretical basis for its further exploitation as a medical plant or nutritional food.